Get the Stockscreener App
3.03
1.94%
-0.06
After Hours:
3.03
Camp 4 Therapeutics Corp stock is traded at $3.03, with a volume of 28,756.
It is down -1.94% in the last 24 hours and down -32.52% over the past month.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$3.09
Open:
$3.12
24h Volume:
28,756
Relative Volume:
0.64
Market Cap:
$61.09M
Revenue:
$264.74M
Net Income/Loss:
$-49.71M
P/E Ratio:
-0.7398
EPS:
-4.0959
Net Cash Flow:
$-43.55M
1W Performance:
-29.37%
1M Performance:
-32.52%
6M Performance:
+657.50%
1Y Performance:
+11.81%
1-Day Range:
$3.01
$3.3041
1-Week Range:
$3.01
$4.378
52-Week Range:
$0.3901
$12.30
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
3.03 | 61.09M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
Manasa Pamboor holds free camp for physiotherapy, speech therapy and counseling - Daijiworld
Free Camp for Physiotherapy, Speech Therapy, and Counselling at Manasa Pamboor - Mangalorean.com
CAMP4 Therapeutics Advances RNA-Based Therapeutics - TipRanks
Promising Developments and Solid Financials Support Buy Rating for CAMP4 Therapeutics - TipRanks
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Gunnison Copper Provides a Construction Update for the Johnson Camp Mine in Southeast Arizona - Yahoo Finance
CAMP4 Appoint Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP To Board - citybiz
Camp4 Therapeutics expands board with two new directors By Investing.com - Investing.com Australia
Camp4 Therapeutics expands board with two new directors - Investing.com
CAMP4 Therapeutics Expands Board with New Director Appointments - TipRanks
Major Leadership Boost: CAMP4 Adds Drug Development Pioneers to Board - StockTitan
Stocks Turn Mixed as Magnificent Seven Stocks Fall - TradingView
Stocks Supported by Strength in Chip Stocks and Lower Bond Yields - TradingView
SMALL CAP IDEA: 'Flu Camp' rapid drug trial firm slashes big pharma costs - This is Money
Orchid Isle Dance Announces Connection Camp in Hawaii: Adventure Travel for the Social Dancer - Yahoo Finance
Stocks Rebound as US Government Shutdown Seems Averted - TradingView
It Might Not Be A Great Idea To Buy Camping World Holdings, Inc. (NYSE:CWH) For Its Next Dividend - Yahoo Finance
KY House passes bill to protect conversion therapy, reverse Beshear’s executive order - Lexington Herald Leader
CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
12 Penny Stocks with Insider Buying in 2025 - Insider Monkey
Home | Department of Parks and Recreation - City and County of Honolulu (.gov)
(PDF) Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways - ResearchGate
RFK's plan to make America healthy again? Send people with mental health conditions to farms - Yahoo
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Fox Chase Cancer Center to Hold Fifth Annual Cancer Epigenetics Symposium - Fox Chase Cancer Center
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
3 Key Healthcare Conferences Where CAMP4 Therapeutics Will Share Its regRNA Innovation - StockTitan
Bay Area biotech firm guts staff, shuts trial after dangerous side effects - SFGATE
Trump to prepare facility at Guantanamo for 30,000 migrants - Reuters
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Top regulator calls for ban on wilderness camps in North Carolina - WBTV
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CAMP4 Therapeutics CEO to Present Corporate Update at J.P. Morgan Healthcare Conference - StockTitan
Here are 71 Mass. life science firms presenting at J.P. Morgan - The Business Journals
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones - The Manila Times
Strategic Investment Boosts Exploration Plans in Ontario's Gold Camp - Streetwise Reports
Camp4 Therapeutics sees MAD safety and key biomarker data in 2H25 - TipRanks
CAMP4 Therapeutics Advances Urea Cycle Disorder Drug After $82M IPO, Secures BioMarin Partnership - StockTitan
CAMP4 Therapeutics Reports Positive Safety Data from CMP-CPS-001 Phase 1 Study and Highlights Key 2025 Milestones - Nasdaq
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors - citybiz
CAMP4 Therapeutics Taps Former Alnylam CEO, RNA Pioneer to Drive Next-Gen Gene Therapy Platform - StockTitan
Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
CAMP4 Therapeutics to Present at Piper Sandler Healthcare Conference in NYC | CAMP Stock News - StockTitan
Meet the Newest Stock in the Nasdaq. It's Soared 918% Since Last Year, and It's Still a Buy Right Now, According to Certain Wall Street Analysts. - The Motley Fool
CAMP4 Reports Third Quarter 2024 Financial Results - The Manila Times
CAMP4 Therapeutics Corporation (CAMP) reports earnings - Quartz
Camp4 Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CAMP4 Therapeutics Secures $370M BioMarin Deal, Raises $82M in IPO Milestone | CAMP Stock News - StockTitan
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Camp 4 Therapeutics Corp Stock (CAMP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AH Equity Partners Bio I, L.L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
727,272 |
7,999,992 |
1,579,885 |
| Enavate Sciences GP, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
3,785,802 |
| Polaris Management Co. VII, L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
| 5AM Partners VI, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
2,625,145 |
| Nashat Amir | Director |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
| Schwab Andrew J. | Director |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
2,625,145 |
| Cohenour Jason | Director |
Jun 05 '24 |
Sale |
0.83 |
8,640 |
7,176 |
0 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):